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ABSTRACT 
Background: To date, no data have been available concerning the psychometric 
characteristics of The Internalized Stigma of Mental Illness scale (ISMI-29) in Latin-America 
countries. The aim of this study was to validate a Latin America version of the ISMI in people 
with schizophrenia. 
Methods: The study included 253 stabilized outpatients with schizophrenia from 3 Mental 
Health Services in three Latin-American countries: Bolivia (N = 83), Chile (N = 85) and Peru 
(N = 85). We analyzed the psychometric properties using item response and classical test 
theories. An item reduction was then performed to improve the psychometric properties of the 
ISMI-29. The final version of the ISMI was tested for construct validity, reliability, external 
validity and differential item functioning (DIF). 
Results: The five-factor structure of the ISMI-29 was not confirmed using confirmatory 
factor analysis (RMSEA=0.12, CFI=0.77, and WRMR=2.20). Seventeen items were 
discarded to obtain a satisfactory psychometric version. The ISMI-12 evaluates 3 dimensions: 
social stigma (4 items), stigma experience (4), and self-stigma (3). The factor structure 
accounted for 68% of the total variance. Internal consistency was satisfactory. The scalability 
was satisfactory, with INFIT statistics within an acceptable range. In addition, the results 
confirmed the absence of DIF and supported the invariance of the item calibrations between 
countries. 
Conclusion: The ISMI-29 is not valid in our sample and should not be used in Latin-America 
countries. The ISMI-12 is the first internalized stigma questionnaire with satisfactory 
psychometric properties available in Latin-America countries. Its brevity could facilitate its 
dissemination and use in clinical settings. 
Keywords: Internalized stigma; Schizophrenia; Psychometric properties; Validity. 
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BACKGROUND 
People with mental illness are exposed to the negative stereotypes of the general 
population about people with mental illness and may internalize them, which yields the so-
called internalized stigmas [1,2]. The findings of a systematic review by Gerlinger and 
colleagues (2013) [3] indicate that from one-third to one-half of patients with schizophrenia 
(SZ) feels shame as a consequence of the disorder [4]. It is also a barrier for early 
antipsychotic treatment onset, and increased duration of untreated psychosis has been 
associated with worse prognosis [5].  
Accurate and appropriate assessment of internalized stigma is thus critical to reduce duration 
of untreated psychosis to improve medico-social programs and to guide public health policies 
for SZ people. The Internalized Stigma of Mental Illness scale (ISMI-29) is one of the most 
widely used measurements of internalized stigma in mental health research [6-9]. To date, the 
psychometric characteristics of the ISMI-29 have not been explored in Latin 
America countries [9]. Two previous works have validated the ISMI-29 in Spanish samples 
[10,11]. If the language is similar, we cannot exclude substantial socio-cultural and economic 
differences between Spain and Latin America countries, influencing the phenomenon of 
stigmatization. In addition, these two previous studies did not report how the factorial 
structure described in their samples fit the initial structure of the tested instrument, which 
remains a key point when considering validity. Restricted data regarding validity and 
reliability were also provided. For these reasons, the extent to which SZ patients in Latin 
America countries can validly self-report their internalized stigma using the ISMI-29 is a 
crucial issue that has not been sufficiently explored. 
The aim of this study was thus to validate a Latin America version of the ISMI in people with 
schizophrenia. 
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METHODS 
Study participants 
Overall, 253 stabilized SZ outpatients were consecutively recruited between May 2012 
and February 2013 in the three public ambulatory psychiatric care centers of three areas: 
Arica, northern Chile (N=85, 33.6%), Tacna, southern of Peru (N=85, 33.6%), and La Paz, 
Central-Western of Bolivia (N=83, 32.8%). The three centers shared similar characteristics in 
terms of size, type of treatment delivered to patients, professionals and free access of care. 
Inclusion criteria 
All stabilized community-dwelling patients diagnosed with schizophrenia according to 
the criteria of International Classification of Diseases (ICD), 10
th
 version [12] were included 
in this study.  
Non-inclusion criteria 
Patients with history of neurological disorders (including stroke, epilepsy and head 
injury) or all illnesses affecting central nervous system were not included in the present study.  
Procedures 
Two psychologists, who were part of the research team, trained for scale evaluation, 
and supervised by the principal researcher (ACU), conducted the evaluations of the 
participants under the auspices of the mental health services of each country. The length of 
time of the evaluation was between 20-30 minutes.  
Data collection 
Demographic and illness characteristics variables 
Age, gender, ethnicity (Aymara and non-Aymara), marital status (with or without 
partner), educational level (≥ 12 years or < 12), employment status (unemployed or 
employed), family income (measure of the total salary per month for all members of the 
family, expressed in US dollars), age at onset the disorder, the number of hospitalizations in 
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the last 3 years were reported. All patients were administered antipsychotics. The presence or 
absence of add-on integrated treatment (defined by psychotherapy, family psychoeducation, 
and/or day care hospital in addition to pharmacological treatment) was also reported.  
Concerning ethnicity, the Aymara is the largest ethnic group in the region, with a 
population of 2 million people, and has lived in the Andes Mountains for centuries. Recent 
generations of Aymara have undertaken a massive migration from rural towns to large cities 
and, thus, receive healthcare services from the same clinics as non-Aymara individuals [13-
15].  
Instruments 
Internalized stigma 
The ISMI-29 Scale is a 29-item instrument with 5 subscales (i.e., alienation (5 items), 
stereotype endorsement, discrimination experience, social withdrawal and stigma resistance) 
and a total score for self-rated assessment of the subjective experience of stigma for people 
with mental illnesses [6]. Each item is rated on a 4-point Likert scale ranging from 1 = 
strongly disagree to 4 = strongly agree with higher scores indicating higher internalized 
stigma. Each score is calculated by adding the item scores together and then dividing by the 
total number of answered items. A high total score on the ISMI scale indicates more severe 
internalized stigmatization. The Spanish version of the ISMI-29 was used in this work [11]. 
Following the method used by Lysaker et al., (2007) [8], 4 categories can be created for each 
score: 1.00-2.00 (minimal to no internalized stigma), 2.01-2.50 (mild internalized stigma), 
2.51-3.00 (moderate internalized stigma), and 3.01-4.00 (severe internalized stigma). 
Following the method used by Ritsher & Phelan (2004) [7], 2 categories can also be created 
for each score: 1.00-2.50 (does not report high internalized stigma), and 2.51-4.00 (reports 
high internalized stigma). 
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Positive and Negative Syndrome scale for Schizophrenia (PANSS) [16]. This 30-item, 7-
point (1–7) rating scale has been specifically developed to assess psychotic symptoms in SZ 
individuals with five factors (positive, negative, cognitive, depressive and excitement 
subscores). The PANSS has been translated and validated in Spain by Peralta and Cuesta 
(1994) [17] and in Mexico by Fresán, et al., 2005 [18].  
Quality of life 
Quality of life (QoL) was assessed using the SQoL18, a self-administered QoL 
questionnaire designed for people with schizophrenia [19] and validated in Latin America 
[20]. QoL score ranges from 0, indicating the lowest QoL, to 100, the highest QoL.  
Statistical analysis 
Socio-demographic and clinical characteristic descriptions were done with frequencies 
and percentages for categorical variables and with means and standard deviations for 
continuous variables. 
The 5-factor structure of the ISMI-29 was verified using confirmatory factor analysis 
(construct validity). The following indicators were required to confirm that this structure 
match with our data. The Root Mean Square Error of Approximation (RMSEA) is acceptable 
if <0.08, the Comparative Fit Index (CFI) is higher than 0.9, and the Weighted Root Mean 
Square Residual (WRMR) is lower than 0.9. Considering previous validation studies in 
different countries [9], we hypothesized that the 5-factor structure initially developed would 
not fit with our data. In this case, the following procedure will be applied. The construct 
validity was assessed using principal component factor analyses with varimax rotation [21], 
in order to determine a new structure and the number of independent dimensions of 
internalized stigma. Eigenvalues greater than or equal to 1 were retained [22]. Descriptive 
statistics were performed to examine the response distribution to each item and dimension. 
The items with the following characteristics were removed: low response rate (<20%), low 
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index discrimination (<0.70), decrease of cronbach’s alpha coefficients, and multiple loading 
(>0.4) of an item on several factors. Once the structure and the number of items are fixed, 
this final version was tested for construct validity, reliability, external validity and 
acceptability. Item-internal consistency (IIC) was assessed by correlating each item with its 
scale (corrected for overlap) using Pearson’s coefficient (correlation of 0.4 recommended for 
supporting item-internal consistency [23]; item discriminant validity was assessed by 
determining the extent to which items correlate more highly with the dimensions they are 
hypothesized to represent than with the other ones [24]. For each dimension scale, internal 
consistency reliability was assessed by Cronbach’s alpha coefficient (coefficient of at least 
0.7 expected for each scale [23]. The uni-dimensionality of each dimension was assessed 
using Rasch analysis. The goodness-of-fit statistics [inlier-sensitive fit (INFIT), ranging 
between 0.7 and 1.3 ensured that all items of the scale measured the same concept. Floor and 
ceiling effects were reported assessing the homogeneous repartition of the response 
distribution. Differential item functioning (DIF) analyses were performed, which compared 
the item differences between groups of individuals according to socio-demographic 
parameters (gender, ethnicity, and country) to check whether all items behave the same way 
[25]. The DIF means that an item performs and measures differently for one subgroup of a 
population than for the other.  
The external validity was assessed by studying relations between dimensions of ISMI 
scores and demographic, illness and QoL characteristics. We also explored the relations 
between ISMI-12 and ISMI-29 scores. Acceptability was determined by proportions of 
missing values.  
All the tests were two-sided. Statistical significance was defined as p<0.05. The 
statistical analyses were performed using the SPSS version 20.0 software package (SPSS Inc., 
Chicago, IL, USA) and Mplus Software. 
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RESULTS 
Sample characteristics  
Two hundred and fifty-three SZ patients were enrolled in this study. The 
sociodemographic and clinical features are listed in table 1.  
Construct validity of the ISMI-29 
The five-factor structure of the ISMI-29 was not confirmed using confirmatory factor 
analysis: RMSEA=0.12, CFI=0.77, and WRMR=2.20. Cronbach’s alpha coefficients were not 
satisfactory (discrimination experience=0.47, social withdrawal=0.68, and stigma 
resistance=0.67), except for two dimensions (alienation=0.73, and stereotype 
endorsement=0.72). 
Item reduction of the ISMI-29 
Seventeen items were discarded for the following reasons: 5 items for low index 
discrimination, 12 items were deleted after examination of items’ structure using the principal 
component analyses (4) and Cronbach’s alpha coefficients (8). The final version contained 12 
items (ISMI-12). 
Construct validity, internal structural validity and reliability of the ISMI-12 
The results are summarized in Table 2. The structure of the ISMI-12 was confirmed by 
principal component factor analysis, identifying a 3-factor structure accounting for 68% of the 
total variance. The dimensions were named according to their constitutive items: social stigma 
(4 items), stigma experience (4 items), and self-stigma (3 items). The 12 items are detailed in 
the Appendix. Internal consistency was satisfactory for all dimensions: each item achieved the 
0.40 standard for item-internal consistency. The correlation of each item with its contributive 
dimension was higher than with the others (item discriminant validity). Floor effect ranged 
from 16.6 to 27.9% and ceiling effect from 19.5 to 29.2%. Cronbach’s alpha coefficients 
ranged from 0.77 to 0.88, indicating satisfactory internal consistency. The overall scalability 
9 
 
was globally satisfactory: no items showed an INFIT statistic outside the acceptable range 
except for 2 items and country.   
According Lysaker, et al., (2007) [8], 23.4% (57) of individuals had minimal to no 
internalized stigma, 27.0% (66) had mild internalized stigma, 25.0% (61) had moderate 
internalized stigma, and 24.6 (60) had severe internalized stigma. Following the method used 
by Ritsher & Phelan, 2004 [7], 50.4% (123) did not report high internalized stigma, and 
49.6% (121) reported high internalized stigma. 
External validity of the ISMI-12 
The results are summarized in Table 3. Higher psychotic symptomatology, lower 
quality of life, and lower family income were associated with internalized stigma. Men had 
higher social withdrawal than women, Aymara had higher alienation than non-Aymara, and 
employment was associated with lower internalized stigma.  
The correlations between the scores of ISMI-12 and ISMI-29 are presented in Table 4. 
All the dimensions were significantly correlated (r ranged from 0.18 to 0.97). The total scores 
of ISMI-12 and ISMI-29 were highly correlated (r=0.93). The 3 dimensions of the ISMI-12 
(i.e., social stigma, stigma experience, and self-stigma) were highly correlated with three 
similar dimensions of the ISMI-29 (social withdrawal r=0.98, discrimination experience 
r=0.97, and alienation r=0.92). 
Acceptability 
The proportion of missing values per dimension never exceeded 1.0%. 
 
DISCUSSION 
In this study, we have demonstrated the validity and reliability of ISMI-12 in a large 
multicenter sample of Latin American community-dwelling SZ patients from three countries. 
The ISMI-12 presents interesting characteristics for a widespread use in SZ patients in Latin 
America. 
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The ISMI-12 is one of the shortest instruments among stigma measures, including the Self-
stigma of Mental Illness Scale (SSMIS, 40 item) [26], the Consumer Experiences of Stigma 
Questionnaire (CESQ, 20 items) [27], the Depression Self-stigma Scale (DSSS, 32 items) 
[28], the Stigma Scale (SS, 28 items) [29] and the Discrimination and Stigma Scale (DISC, 36 
items) [30,31]. According to several authors, a short form of a scale is frequently associated 
with better acceptability [32]. The average completion time is expected to be less than 5 
minutes and this will facilitate its use in routine clinical practice. 
The internal structure retrieved several important dimensions of stigma for patients. The 
classification of the items is different from that of the ISMI-29 and may add a complementary 
approach to this scale. This new classification appears transversal to the different dimensions 
(i.e., alienation, stereotype endorsement, discrimination experience, social withdrawal and 
stigma resistance) of the ISMI-29 (trans-dimensional), with a grouping more centred on the 
patient's experience rather than on a theoretical and conceptual approach of the stigma. The 
first dimension addresses the social aspect of stigma while the ISMI-29 focused on social 
withdrawal. In this dimension (i.e., social stigma), items explored social dependency (item 1), 
social withdrawal (item 2 and 3), and social exclusion (items 4 and 5). Previous studies 
reported the importance of the social issue in the phenomenon of stigmatization: social 
anxiety, social withdrawal, and lower social functioning [3]. The second dimension is about 
experience of stigma including items discrimination (items 6, 7 and 9) and negative belief 
about the self (item 8). Previous studies reported the closely link between discrimination and 
the impact on self-esteem and stereotype [1]. The third dimension is related to self-stigma in 
accordance with the definition proposed by Corrigan and Watson (2002) [1]: an 
“internalisation of public stigma” or as “the product of internalization of shame, blame, 
hopelessness, guilt and fear of discrimination associated with mental illness”. Lastly, we can 
also note that the majority of items on stigma resistance were discarded, confirming that 
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stigma resistance do not function like a subdimension of internalized stigma of mental illness 
construct [33]. 
Concerning the psychometric properties, our proposal meets standards. The internal structure 
was supported by a high internal consistency. Internal consistency reliabilities for the three 
dimensions were shown to be high (Cronbach’s alpha>0.77). External validity, explored by 
the use of demographic, illness and QoL characteristics confirmed results of previous works 
on stigma. As expected, patients with higher psychotic symptoms had higher scores of 
stigmatization. Like other studies, a number of reasons are raised in relation to this point: 
thus, the greater the number of symptoms, the more likely it is to be the target of stigma from 
others, which would increase the probability of greater self-stigma, being more difficult for 
the patient to formulate positive beliefs about them. Conversely, if the patient has a lower 
internalized stigma, he / she is likely to be able to manage the symptoms more effectively, 
reducing its severity [8]. Higher scores of stigmatization were associated with lower quality of 
life. This result is consistent with previous studies showing reduced subjective quality of life 
mediated by perceived stigma and low self-esteem in SZ subjects [4, 34-38].  
There are several limitations of this study. The sample may not be representative of the entire 
population of SZ patients (only public sector in medium–large cities) and more globally of the 
entire population in Latin America. Moreover, the patients in the study sample were mostly 
middle-aged males with mild disease severity and long illness duration. Confirmation is 
required for more miscellaneous and larger groups of patients. In particular, further work is 
needed to test the ISMI-12 in other important South American countries like, Colombia and 
Venezuela. Future studies should incorporate patients from the private sector given the 
marked social differences especially in Latin America. The “responsiveness” or “sensitivity to 
change” defined as the ability to detect a meaningful change, is a core psychometric property 
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of a measuring instrument that we did not explore in this study. Its examination is required in 
future studies using longitudinal data collection. 
CONCLUSION 
The ISMI-12 is the first internalized stigma questionnaire with satisfactory 
psychometric properties available for SZ individuals in Latin America countries. Its brevity 
may be appropriate and useful for research and clinical practices.  
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Table 1. Socio-demographic and clinical characteristics of the study sample (N=253) 
Patients Mean ± SD, median [IQR] or n 
(%)* 
Age in years 35.6 ± 12.5 
Gender  Women 83 (33.6) 
 Men 164 (66.4) 
Ethnicity  Non-Aymara 136 (53.8)  
 Aymara 117 (46.2) 
Marital Status  Without a partner 237 (93.7) 
 With a partner  16 (6.3)  
Educational level  ≥ 12 years 40 (15.8) 
 < 12 years 213 (84.2) 
Employment status With employment   78 (31.2) 
 Without employment   172 (68.8) 
Monthly family income (US 
dollars) 
 331.3 [144.9 ; 517.9] 
Age at onset of the disease  20.9 ± 6.4 
Number of hospitalizations  1 [2 ; 0] 
Type of mental health treatment Integrated  31 (12.3) 
 Only pharmacological  222 (87.7) 
Symptoms severity PANSS total score 71.3 ± 28.2 
 Positive factor 8.3 ± 4.6 
 Negative factor 18.6 ± 8.4 
 Depressive factor 6.4 ± 3.7 
 Cognitive factor 7.3 ± 4.0 
 Hostile-excitement 
factor 
11.5 ± 5.9 
Quality of life S-QoL 18 index 54.3 ±  14.4 
* Mean ± SD: mean ± standard deviation; median [IQR]: median [Inter Quartile Range]; n (%): effective 
(percentage). 
PANSS: Positive and Negative Syndrome scale for Schizophrenia.  
S-QoL18: Schizophrenia Quality of Life questionnaire. 
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Table 2. Dimension characteristics of the ISMI 
Dimension/index 
(number of items) 
M (SD) Missing 
values 
% 
Item-internal consistency  
(min-max) 
Item discriminant validity 
(min-max) 
Floor  
% 
Ceiling  
% 
Alpha* INFIT**  
(min-
max) 
Dimension 1: social stigma (4) 2.8 (0.9) 0.8 0.67-0.77 0.24-0.46 16.6 29.2 0.88 0.82-1.25 
Dimension 2: stigma 
experience (4) 
2.5 (0.8) 0.6 0.55-0.61 0.32-0.44 24.3 19.5 0.77 0.85-1.08 
Dimension 3: self-stigma (3) 2.4 (1.0) 0.7 0.67-0.75 0.24-0.47 27.9 21.9 0.85 0.87-1.19 
Index (12) 2.6 (0.7) 0.7 NA*** NA*** NA*** NA*** 0.88  NA*** 
*Cronbach’s Alpha, **Rasch’s statistics, *** NA Not Applicable 
M (SD) mean (standard deviation); a higher score represents a higher level of unawareness. 
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Table 3. External validity of the ISMI dimension scores and index 
 Dimension 1: social 
stigma 
Dimension 2: stigma 
experience 
Dimension 3:  
self-stigma 
Index 
Symptoms severity PANSS total score 0.26** 0.33** 0.24** 0.33** 
 Positive factor 0.24** 0.30** 0.22** 0.30** 
 Negative factor 0.31** 0.24** 0.18** 0.30** 
 Depressive factor 0.18** 0.26** 0.19** 0.27** 
 Cognitive factor 0.13* 0.27** 0.22** 0.23** 
 Hostile-excitement factor 0.01 0.18** 0.13* 0.12 
Quality of life S-QoL 18 index -0.38** -0.47** -0.42** -0.51** 
Age  (years) 0.08 0.11 -0.07 0.04 
Monthly family income (US dollars) -0.21** -0.11 -0.14* -0.21** 
Age at onset of the disease (years) -0.02 -0.07 -0.04 -0.07 
Number of hospitalizations 0.09 0.04 0.02 0.05 
Gender Men 2.9 (0.8) 2.4 (0.8) 2.4 (1.0) 2.6 (0.7) 
 p-value 0.009 0.499 0.865 0.303 
Ethnicity  Aymara 2.8 (0.9) 2.5 (0.7) 2.6 (0.9) 2.7 (0.7) 
 p-value 0.220 0.590 0.011 0.072 
Marital Status With a partner  2.8 (0.8) 2.7 (0.7) 2.5 (1.0) 2.7 (0.5) 
 p-value 0.719 0.239 0.738 0.431 
Education level < 12 years 2.8 (0.9) 2.5 (0.8) 2.5 (1.0) 2.6 (0.7) 
 p-value 0.177 0.106 0.068 0.062 
 With employment   2.5 (0.9) 2.2 (0.8) 2.2 (0.9) 2.3 (0.7) 
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Employment status Without employment   2.9 (0.8) 2.6 (0.8) 2.5 (1.0) 2.7 (0.7) 
 p-value 0.001 0.001 0.016 <0.001 
Mental health  Only pharmacological 2.8 (0.9) 2.4 (0.8) 2.4 (1.0) 2.6 (0.7) 
treatment p-value 0.630 0.460 0.354 0.803 
      
PANSS: Positive and Negative Syndrome scale for Schizophrenia.  
S-QoL18: Schizophrenia Quality of Life questionnaire. 
Bold values p<0,05, *p<0.05, **p<0.01 
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Table 4. Correlations between the scores of ISMI-12 and ISMI-29 
 
ISMI-12 
ISMI-29 
Dimension 1: 
social stigma 
Dimension 2: stigma 
experience 
Dimension 3: 
self-stigma 
Index 
Alienation .439
**
 .616
**
 .921
**
 .787
**
 
Stereotype endorsement .346
**
 .522
**
 .580
**
 .574
**
 
Discrimination experience .546
**
 .972
**
 .522
**
 .836
**
 
Social withdrawal .983
**
 .535
**
 .352
**
 .832
**
 
Stigma resistance .176
**
 .343
**
 .315
**
 .312
**
 
Total .700
**
 .800
**
 .739
**
 .930
**
 
*p<0.05, **p<0.01 
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Appendix 1. Latin America version of the ISMI: ISMI-12 
Items ISMI-12 (English) Items ISMI-12 (Spanish) Corresponding item in the ISMI-29 Dimensions 
1. Because I have a mental illness, I 
need others to make most decisions 
for me. 
Debido a que tengo una enfermedad 
mental, necesito que los demás tomen 
la mayoría de decisiones por mí 
Item 19 Dimension 1: social stigma 
2. I stay away from social situations 
in order to protect my family or 
friends from embarrassment. 
Me mantengo apartado de situaciones 
sociales con el fin de no avergonzar a 
mi familia o amigos 
Item 20 Dimension 1: social stigma 
3. People without mental illness 
could not possibly understand me. 
Las personas sin enfermedad mental 
no pueden entenderme 
Item 21 Dimension 1: social stigma 
4. People ignore me or take me less 
seriously just because I have a mental 
illness. 
La gente me ignora o me toma menos 
en serio sólo porque tengo una 
enfermedad mental 
Item 22 Dimension 1: social stigma 
5. Living with mental illness has 
made me a tough survivor. 
Vivir con una enfermedad mental me 
ha hecho una persona fuerte 
Item 24 Dimension 1: social stigma 
6. I feel comfortable being seen in 
public with an obviously mentally ill 
person. 
Me siento cómodo si me ven en 
público con una persona que es 
evidente que tiene enfermedad 
mental 
Item 14 Dimension 2: discrimination stigma 
7. People often patronize me, or treat 
me like a child, just because I have a 
mental illness. 
La gente a menudo tiene una actitud 
paternalista conmigo, o me trata 
como a un niño, solo porque tengo 
una enfermedad mental 
Item 15 Dimension 2: discrimination stigma 
8. I am disappointed in myself for 
having a mental illness. 
Estoy decepcionado conmigo mismo 
por tener una enfermedad mental 
Item 16 Dimension 2: discrimination stigma 
9. People can tell that I have a mental 
illness by the way I look. 
La gente puede decir que tengo una 
enfermedad mental por mi aspecto 
Item 18 Dimension 2: discrimination stigma 
10. I avoid getting close to people 
who don’t have a mental illness to 
avoid rejection. 
Evito relacionarme con personas que 
no tienen enfermedad mental para 
evitar el rechazo 
Item 4 Dimension 3: self-stigma 
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11. I am embarrassed or ashamed that 
I have a mental illness. 
Estoy avergonzado de tener una 
enfermedad mental 
Item 5 Dimension 3: self-stigma 
12. Mentally ill people shouldn’t get 
married. 
Las personas con enfermedad mental 
no deberían casarse 
Item 6 Dimension 3: self-stigma 
 
 
